Dr Carmela Ricciardelli
FHMS 2025 Mature Grant Development Award
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
My postdoctoral studies were undertaken in the Department of Surgery, Flinders Medical Centre, South Australia and Dame Roma Mitchell Cancer Research Laboratories, Hanson Institute, South Australia (1996-2003) and I joined the Discipline of Obstetrics and Gynecology, University of Adelaide in 2005. I have received highly competitive fellowships in the Faculty of Health Sciences, University of Adelaide and Cancer Council SA (2004-2014) which have enabled me to build a Reproductive Cancer research group in the Discipline of Obstetrics and Gynaecology, University of Adelaide. I was recently awarded the inaugural Lin Huddleston Ovarian Cancer Research Fellowship,Cancer Council SA (2016-2020).
Dr Ricciardelli a cancer cell biologist; joined the Discipline of Obstetrics and Gynaecology in April 2005. She was awarded her Ph D in 1996 (Flinders University) and has undertaken postdoctoral studies in the Department of Surgery, Flinders Medical Centre, South Australia (1996-2001) and Dame Roma Mitchell Cancer Research Laboratories, Hanson Institute, South Australia (2002-2005). In 2005 Dr Ricciardelli was awarded a Tall Poppy Award for outstanding achievement in the field of biomedical and clinical science. In 2007 she was the recipient of the highly competitive Hilda Farmer Fellowship in Faculty of Health Sciences, University of Adelaide which has enabled her to build a Reproductive cancer research group in the Discipline of O&G, University of Adelaide. In 2012 Dr Ricciardelli was awarded a senior fellowship funded by SAHMRI and Cancer Council SA. In 2015 Dr Ricciardelli was awarded the Lin Huddleston Ovarian Cancer Fellowship funded by Cancer Council SA & Adelaide Medical School, University of Adelaide
Dr Ricciardelli's research program has focused on hormone-regulated proteins and prognostic markers in breast and prostate cancer. Using a novel approach in her postdoctoral studies by examining the non-cancer stromal cells which surround the cancer cells, Dr Ricciardelli was the first researcher to identify that the expression of the extracellular matrix protein, versican correlated with cancer spread in prostate and breast cancer. This was an exciting and unique discovery that has lead to versican expression being examined in many different cancer types. Versican is a molecule known to regulate cellular movement at critical periods in the developing embryo, and control the movement of normal smooth muscle cells, nerves and fibroblasts. Dr Ricciardelli's recent studies suggest that cancer cells can utilize stromally derived versican to aid their movement.
Dr Ricciardelli current research focuses on further understanding the cross-talk between breast and ovarian cancer cells and the tumour microevironment.The Reproductive Cancer Group seeks to understand the mechanisms involved in ovarian cancer spread, resistance to chemotherapy and the identification of novel biomarkers for early detection.
Project 1
Title: Extracellular vesicles: Identification of novel biomarkers and therapeutic targets for serous ovarian cancer
Description: Extracellular versicles (EVs) are nano-sized membrane-bound particles produced by virtually all cells in the body. They are found in all bodily fluids including the blood of ovarian cancer patients. EVs provide a major route of communication between different cell types throughout the body as they contain DNA, protein, RNA and lipid cargo characteristic of their cells of origin, which can be transferred to distant cells and affect their function. Extracellualr vesicles (EVs) are found in increasing numbers in the blood circulation under certain conditions, e.g. during normal pregnancy, and in cancer. The RNA and protein content of EVs have been characterised in studies of various commercially available cancer cell lines, including ovarian cancer cells; but few studies to date have focussed on ovarian cancer patient blood samples. This study will examine the proteomic profile in EVs isolated from patients with diagnosed late stage serous ovarian cancer, compared to benign serous cystadenomas and healthy controls. Candidate proteins that are differentially expressed will be validated and further characterized in ovarian cancer patient cohorts and using functional assays (adhesion, migration and invasion assays).
Location: Adelaide Health and Medical Science Building , North Terrace
Research project start: Semester 1 & 2
Project 2
Title: CAR-T cells targeting GPC1 a novel therapeutic approach against ovarian cancer
High serous ovarian carcinoma (HGSOC) makes up nearly 70% of ovarian cancers and up to 90% of patients present with advanced disease (FIGO stage III & IV). Current clinical practice for HGSOC consists of de-bulking surgery followed by combined platinum and taxane-based chemotherapy. Although initial responses to 1st line treatment is high, over 75% of patients eventually relapse and acquire chemotherapy resistance, which is the primary cause of ovarian cancer death and a major limitation to the successful treatment of ovarian cancer. Novel treatment strategies that are effective in chemotherapy resistant disease therefore would have immense potential to improve survival.
Chimeric antigen receptor T (CAR-T) based immunotherapies are a revolutionary personalised approach to targeting and destroying cancer cells, with the potential to eradicate cancer without the need for chemotherapy. CART cell therapy targeting CD19 has been very effective against blood cancers, inducing complete remissions in clinical trials in more than 90% of patients, where conventional treatment had failed. CAR-T cell therapies have so far been less effective against solid cancers, due in part to the absence of suitable tumour associated antigens (TAAs) on solid cancers and the physical barriers to CAR-T cells reaching their target.
We have identified a TAAs (glypican-1, GPC1) that has high potential to be a suitable CAR-T cell target for HGSOC. CAR-T cells targeting GPC1 have great potential to be an effective therapy for HGSOC. This study will assess whether GPC1 CAR-T cells can suppress the growth of chemotherapy resistant ovarian cancer in 3D spheroids and inhibit tumour burden and persist in chemotherapy resistant patient derived xenografts in vivo.
Location: Adelaide Health and Medical Science Building , North Terrace
Research project start: Semester 1 & 2
Project 3
Title: Novel therapeutics for ovarian cancer targeting annexin A2
Description: Ovarian cancer caused 207,252 deaths worldwide in 2020. Current treatments consist of surgery followed by chemotherapy, but over 75% of patients relapse and acquire chemotherapy resistance. There is an urgent need for more efficient treatment strategies against ovarian cancer. Our research focuses on understanding the crosstalk between ovarian cancer cells and the tumour microenvironment. Using proteomics approach, we identified annexin A2 to be upregulated by ovarian cancer cells when they interact with the peritoneum, and thereby promoting metastasis. High annexin A2 expression has been associated with poor survival in ovarian cancer patients.
This project will investigate the effects of annexin A2 inhibition in ovarian cancer cell lines and knockdown of annexin A2 expression will be confirm using RT-PCR and western blot. The effects of annexin A2 inhibition will be examine using functional assays including 3D spheroids assays, cell proliferation and apoptosis assay, cell motility and invasion assay and the chick chorioallantoic membrane (CAM) assay. This project will evaluate the efficacy of annexin A2 inhibitors to block ovarian cancer progression and metastasis.
Location: Adelaide Health and Medical Sciences Building, North Terrace
Co-supervisors: Dr Noor Lokman, Prof Martin Oehler
Research project start: Semester 1 and 2
Available for: Third year and Honours
| Date | Position | Institution name |
|---|---|---|
| 2016 - 2020 | Lin Huddleston Ovarian Cancer Fellow | University of Adelaide |
| 2015 - 2015 | Lloyd Cox Senior Research Fellow | University of Adelaide |
| 2012 - 2014 | Cancer Council South Australia Senior Fellow | University of Adelaide |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2010 | Award | Most Outstanding Contribution to the Discipline of Obstetrics and Gynaecology | - | - | - |
| 2008 | Award | Travel award Cancer Council SA | - | - | - |
| 2006 | Fellowship | Hilda Farmer University Fellowship, University of Adelaide | - | - | - |
| 2005 | Award | Tall Poppy award, Australian Institute of Political Science for outstanding achievement in the field of biomedical and clinical science | - | - | - |
| 2003 | Fellowship | Cancer Research Fellowship, Cancer Council South Australia | - | - | - |
| 1992 | Scholarship | Flinders University Scholarship (Postgraduate) | - | - | - |
| 1986 | Award | Martin Hansen Award for Dux of Class in B App Science in Medical Laboratory Science (Australian Institute of Medical Laboratory Science) | - | - | - |
| Language | Competency |
|---|---|
| Italian | Can read, write, speak and understand spoken |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 1996 | Flinders University | Australia | Ph D |
| 1986 | University of South Australia | Australia | B Appl Science |
| Year | Citation |
|---|---|
| 2025 | Khetan, R., Eldi, P., Lokman, N., Ricciardelli, C., Oehler, M., Blencowe, A., . . . Albrecht, H. (2025). Leveraging GPCR overexpression for personalized nanomedicine: A novel approach in ovarian cancer therapy. In CANCER RESEARCH Vol. 85 (pp. 2 pages). IL, Chicago: AMER ASSOC CANCER RESEARCH. DOI |
| 2025 | Khetan, R., Lokman, N. A., Eldi, P., Price, Z. K., Oehler, M. K., Brooks, D. A., . . . Albrecht, H. (2025). Protease-activated receptor F2R/PAR1 is a potential target for new diagnostic/prognostic and treatment applications for patients with ovarian cancer. In CANCER RESEARCH Vol. 85 (pp. A36). AMER ASSOC CANCER RESEARCH. DOI |
| 2023 | Thompson, E. J., Bandara, V., Gundsambuu, B., Napoli, S., Mills, S., Foeng, J., . . . Bonder, C. S. (2023). Assessing LGR5 expression levels on colorectal cancer tissue samples for use in LGR5-targeting CAR-T cell therapy clinical trial. In CANCER RESEARCH Vol. 83 (pp. 2 pages). Orlando, FL: AMER ASSOC CANCER RESEARCH. DOI WoS1 |
| 2022 | Wang, W., Bandara, V., Lokman, N., Napoli, S., Gundsambuu, B., Oehler, M., . . . Ricciardelli, C. (2022). LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer.. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Thompson, E. J., Bandara, V., Sadlon, T., Gundsambuu, B., Tan, L. Y., Ricciardelli, C., . . . Bonder, C. S. (2022). Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors. In CANCER RESEARCH Vol. 82 (pp. 1 page). LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Thompson, E. J., Bandara, V., Sadlon, T., Gundsambuu, B., Tan, L. Y., Ricciardelli, C., . . . Bonder, C. S. (2022). Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors.. In CANCER RESEARCH Vol. 82 (pp. 1 page). LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2022 | Wang, W., Bandara, V., Lokman, N., Napoli, S., Gundsambuu, B., Oehler, M., . . . Ricciardelli, C. (2022). LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH. |
| 2021 | Khan, S., Yool, A., & Ricciardelli, C. (2021). EXPRESSION OF AQUAPORINS IN HUMAN ENDOMETRIAL CANCER: IDENTIFICATION AND REGULATION BY OVARIAN HORMONES IN CARCINOGENESIS OF ENDOMETRIAL CANCER. In INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Vol. 31 (pp. A75). BMJ PUBLISHING GROUP. DOI |
| 2019 | Lokman, N., Ho, R., Gunasegaran, K., Bonner, W., Oehler, M., & Ricciardelli, C. (2019). All trans retinoic acid promotes apoptosis and inhibits serous ovarian cancer invasion. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 36 (pp. 152). SPRINGER. |
| 2011 | Ricciardelli, C., Lokman, N. A., Ween, M. P., Hoffman, P., & Oehler, M. K. (2011). Role of annexin A2 in ovarian cancer metastasis. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 28 (pp. 215). SPRINGER. |
| 2011 | Patterson, K., Sakko, A., Ricciardelli, C., Proudman, S., & Hissaria, P. (2011). EVALUATION OF ANGIOGENIC AND FIBROGENIC CYTOKINES AS BIOMARKERS IN SUBGROUPS OF SYSTEMIC SCLEROSIS. In INTERNAL MEDICINE JOURNAL Vol. 41 (pp. 9-10). WILEY-BLACKWELL. |
| 2009 | Ricciardelli, C., Frewin, K., Ingman, W., & Russell, D. L. (2009). Role of Adamts1 in mammary cancer growth and metastasis. In CLINICAL & EXPERIMENTAL METASTASIS Vol. 26 (pp. 922). SPRINGER. |
| 2006 | Murphy, N., Bianco-Miotto, T., Ricciardelli, C., Ruiz, A., Segara, D., McNeil, C., . . . Tilley, W. (2006). Expression of the androgen receptor and its association with disease outcome in breast cancer. In Breast Cancer Research and Treatment Vol. 100 (pp. S262-S263). San Antonio, Texas: Springer. |
| Year | Citation |
|---|---|
| 2024 | Wang, W. J., Bandara, V., Lokman, N. A., Price, Z. K. K., Noye, T. M., Napoli, S., . . . Ricciardelli, C. (2024). CAR-T cells targeting LGR5: An effective treatment for chemotherapy resistant ovarian cancer. Poster session presented at the meeting of Proceedings of the American Association for Cancer Research Annual Meeting (AACR, 2024) as published in Cancer Research. San Diego, California: American Association for Cancer Research. DOI |
| 2021 | Khan, S., Ricciardelli, C., & Yool, A. (2021). EPV114/# 325 Expression of aquaporins in human endometrial cancer: identification and regulation by ovarian hormones in carcinogenesis of endometrial cancer. Poster session presented at the meeting of International gynaecological cancer society. |
| 2021 | Khan, S., Ricciardelli, C., & Yool, A. (2021). Fuling inhibits invasion in endometrial cancer cells.. Poster session presented at the meeting of EMBL Australia. |
| 2021 | Khan, S., Ricciardelli, C., & Yool, A. (2021). Fuling inhibits invasion in endometrial cancer cells. Poster session presented at the meeting of Australian Metastasis Research Society (OzMRS). |
| 2021 | Khan, S., Ricciardelli, C., & Yool, A. (2021). Fuling inhibits invasion in endometrial cancer cells. Poster session presented at the meeting of Australian Physiological society (AuPS) (oral presentation). |
| 2021 | Khan, S., Ricciardelli, C., & Yool, A. (2021). Identification of Aquaporins in human endometrial cancer and regulation by ovarian hormones in carcinogenesis.. Poster session presented at the meeting of The Australian Society for Medical Research National Scientific Conference, Adelaide, Australia.. |
| 2019 | Lokman, N. A., Ho, R., Gunasegaran, K., Bonner, W. M., Oehler, M. K., & Ricciardelli, C. (2019). ANTI-TUMOUR EFFECTS OF ALL-TRANS RETINOID ACID, AN ANNEXIN A2-S100A10 PATHWAY INHIBITOR ON SEROUS OVARIAN CANCER. Poster session presented at the meeting of CLINICAL CANCER RESEARCH. Seattle, WA: AMER ASSOC CANCER RESEARCH. |
| 2018 | Zhang, A., Chiam, K., Haupt, Y., Fox, S., Birch, S., Tilley, W., . . . Kench, J. (2018). An analysis of multiple biomarkers to better predict prostate cancer metastasis after radical prostatectomy. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. Adelaide: Wiley. |
| 2015 | Lokman, N. A., Elder, A. S. F., Ween, M. P., Pyragius, C. E., Hoffmann, P., Ruszkiewicz, A., . . . Ricciardelli, C. (2015). Annexin A2 a potential prognostic marker for serous ovarian cancer promotes ovarian cancer metastasis. Poster session presented at the meeting of CLINICAL & EXPERIMENTAL METASTASIS. SPRINGER. WoS1 |
| 2015 | Ricciardelli, C., Cheruvu, S., Lokman, N. A., Ween, M. P., Tan, I. A., Pyragius, C. E., . . . Oehler, M. K. (2015). Transketolase a protein regulated by ovarian cancer-peritoneal interactions is elevated in omental metastases and regulates serous ovarian cancer proliferation. Poster session presented at the meeting of CLINICAL & EXPERIMENTAL METASTASIS. SPRINGER. |
| 2014 | Lokman, N. A., Elder, A. S. F., Ween, M. P., Pyragius, C. E., Hoffmann, P., Ruszkiewicz, A., . . . Oehler, M. K. (2014). ANNEXIN A2 A POTENTIAL PROGNOSTIC MARKER FOR SEROUS OVARIAN CANCER PROMOTES OVARIAN CANCER METATASIS. Poster session presented at the meeting of INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. LIPPINCOTT WILLIAMS & WILKINS. |
| 2008 | Hickey, T., Butler, M., Ricciardelli, C., Norman, R., & Tilley, W. (2008). Expression of small glutamine-rich tetratricopeptide repeat-containing protein alpha (alpha SGT), a novel regulator of androgen receptor (AR) activity, in the human ovary and fallopian tube. Poster session presented at the meeting of Biology of Reproduction. Kailua-Kona, Hawaii: Oxford University Press. DOI WoS1 |
| 2006 | Buchanan, G., Ricciardelli, C., Prescott, J., Harris, J. M., Yu, Z. C. -L., Jia, L., . . . Tilley, W. D. (2006). αSGT: A critical determinant of androgen receptor function in prostate cancer. Poster session presented at the meeting of Cancer Research. Washington, DC: American Association for Cancer Research. |
|
Date |
Project/ No. | Investigators | Funding Body | Amount |
|---|---|---|---|---|
| 2011 | Extracellular matrix-macrophage cross talk in the mammary gland |
Ingman WV, Ricciardelli C, Sharkey D, Russell DL |
Robinson Institute (Collaborative Funding scheme) |
$12,000 |
| 2011 | Infrared fluorescence imager for protein quantitation and cultured cell or whole animal imaging |
Russell DL, Robertson S, Thompson J, Rodgers RJ, Roberts C, Norman R, Gilchrist R, Kennaway D, Ingman WV, M ottershead D, Lane M, Robker RL, Ricciardelli C, Oehler MK |
NHMRC equipment grant | $35000 |
| 2011-2012 | Control of breast cancer density and cancer risk by epithelial-stromal interactions |
WV Ingman, M Pike, Ricciardelli C *, Russell DL *, Sharkey D *, Tilley WD*, Wu A* |
National Breast Cancer Foundation (Novel concept award) |
$199,772 |
| 2012 |
Hyaluronan: a marker of ovarian cancer chemoresistance |
Ricciardelli C, Oehler MK |
RAH Clinical Research Fund |
$23,000 |
| 2012 | High throughput image analysis system for histoquantification of histology images |
Ricciardelli C, Owens J, Wittert G, Roberts CT, Tilley WD, Callen D, Russell DL, Ingman WV, Rodgers RJ, Keefe D, Findlay D |
NHMRC equipment grant (GNT 1038556) Faculty of Health Sciences Robinson Institute |
$60,000
$15,000
$20,200 |
| 2012 |
Annexin A2: a novel biomarker and therapeutic target for ovarian cancer |
Ricciardelli C, Oehler MK, Rodgers RJ |
Cancer Council SA/SAHMRI |
$93,723 |
| 2012-2013 | Targeting the cancer peritoneal interaction |
Ricciardelli C, Oehler MK, Hoffmann P |
SAHMRI/OCRF | $50,000 |
| 2013 |
Hyaluronan: a marker and therapeutic target to overcome ovarian cancer chemoresistance |
Ricciardelli C, Oehler MK, Heinzelmann-Schwarz V, Stephens A * |
Cancer Council SA/SAHMRI |
$93,891 |
| 2013-2014 |
Targeting the interaction between breast cancer and Toll-like receptors of the immune system to prevent metastasis |
Russell DL, Ricciardelli C, Hutchinson M |
SAHMRI | $40,000 |
| 2013 |
Targeting the annexin A2 signalling pathway to block ovarian cancer metastasis |
Ricciardelli C, Oehler MK |
Robinson Institute | $13,700 |
| 2014 | The annexin A2 signalling pathway: Novel biomarkers and therapeutic targets for serous ovarian cancer |
Ricciardelli C, Oehler MK, Rodgers RJ |
Robinson Research Institute | $22,700 |
| 2015 | Ricciardelli C |
Lloyd Cox Fellowship, School of Paediatrics and Reproductive Health |
$132,367 |
|
| 2015 | Annexin A2 as a novel diagnostic marker for ovarian cancer |
Ricciardelli C, Oehler MK |
Commercial Accelerator Scheme Development grant, Adelaide Research Innovation |
$25,000 |
| 2016-2020 | Tumour-host signalling pathways: Identification of novel ovarian cancer biomarkers and therapeutic targets | Ricciardelli C | Lin Huddleston Ovarian Cancer Fellowship, Cancer Council SA & School of Medicine, University of Adelaide | $750,000 |
| 2018-2020 |
Evaluating CAR-T cells on ovarian cancer using ex vivo and in vivo models |
Oehler MK Ricciardelli C |
CTM@CRC Limited and Carina Biotech | $136,000 |
Dr. Ricciardelli has been actively teaching undergraduates in the 3rd Year unit Human reproduction III of the Bachelor of Health Science degree (lecturing and workshops) since 2007.
- Problem based learning (PBL) tutor in School of Medicine, Flinders University of SA, Endocrinology, 1999
- Human Reproduction III course, University of Adelaide Lecture “Cancer: Incidence, Development and Treatment” 2007-present
- Human Reproduction III course, University of Adelaide Workshop “Fertility preservation in patients diagnosed with cancer” 2007-present
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2025 | Principal Supervisor | Development of mesothelial cell-targeted therapy to overcome peritoneal dissemination of ovarian cancer | Doctor of Philosophy under a Jointly-awarded Degree Agreement with | Doctorate | Full Time | Ms Marina Yoshikawa |
| Date | Role | Research Topic | Program | Degree Type | Student Load | Student Name |
|---|---|---|---|---|---|---|
| 2021 - 2025 | Principal Supervisor | Elucidation of a novel mechanism of peritoneal dissemination and platinum resistance of ovarian cancer by tumor-associated fibrosis (TAF) Cancer, Fibrosis and Women's Health Care | Doctor of Philosophy under a Jointly-awarded Degree Agreement with | Doctorate | Full Time | Mr Hiroki Fujimoto |
| 2020 - 2024 | Co-Supervisor | Developing Novel Conservative Treatments For Endometrial Cancer By Targeting Aquaporin-1 | Doctor of Philosophy | Doctorate | Full Time | Ms Sidra Nawaz Khan |
| 2020 - 2024 | Principal Supervisor | Development of novel ovarian cancer treatment using CAR-T cells targeting LGR5 | Doctor of Philosophy | Doctorate | Full Time | Ms Wanqi Wang |
| 2018 - 2024 | Principal Supervisor | The Role of Molecular Weight of Hyaluronan in Ovarian Cancer Stem Cell Signalling Pathways and Chemoresistance | Doctor of Philosophy under a Jointly-awarded Degree Agreement with | Doctorate | Full Time | Miss Zoe Kathleen Price |
| 2017 - 2021 | Co-Supervisor | The Role of piRNA Pathway Genes in Ovarian and Prostate Cancer Progression | Doctor of Philosophy | Doctorate | Full Time | Miss Eunice Hsiu Yee Lee |
| 2016 - 2020 | Principal Supervisor | Clinical and Basic Research for Ovarian Cancer | Doctor of Philosophy under a Jointly-awarded Degree Agreement with | Doctorate | Full Time | Mr Masato Yoshihara |
| 2011 - 2014 | Principal Supervisor | Role of Annexin A2 in Ovarian Cancer Metastasis | Doctor of Philosophy | Doctorate | Full Time | Dr Noor Alia Lokman |
| 2010 - 2016 | Co-Supervisor | The Role of Estrogen Receptor and the Androgen Receptor in Human Breast Cancer | Doctor of Philosophy | Doctorate | Part Time | Mrs Shalini Jindal |
| 2010 - 2015 | Co-Supervisor | Utilising Quantitative Immunoproteomics To Reveal Differential Autoantibody Biomarker Panels In Serous Ovarian Cancer Patients | Doctor of Philosophy | Doctorate | Full Time | Mrs Karina Martin |
| 2009 - 2014 | Co-Supervisor | Adamts1 is a promoter of metastatic cell behaviour in mammary cancer cells | Doctor of Philosophy | Doctorate | Full Time | Miss Izza Maria Doreen De Arao Tan |
| 2009 - 2010 | Principal Supervisor | The Biological Role of Extracellular Matrix in Ovarian Cancer Metastasis | Doctor of Philosophy | Doctorate | Full Time | Miss Miranda Ween |
| 2009 - 2012 | Co-Supervisor | The Role of Small Glutamine-Rich Tetratricopeptide Repeat Containing Protein Alpha in Female Reproductive Tissues | Doctor of Philosophy | Doctorate | Full Time | Ms Miriam Simone Butler |
| 2007 - 2010 | Co-Supervisor | The Role of Epigenetic Modifications in Prostate Tumourigenesis | Doctor of Philosophy | Doctorate | Full Time | Ms Karen Huiqin Chiam |
| 2004 - 2009 | Co-Supervisor | Functional Analysis of CBFA2T3: A Breast Cancer Tumour Suppressor from Chromosome Band 16q24.3 | Doctor of Philosophy | Doctorate | Full Time | Dr Zarqa Saif |
| 2002 - 2004 | Co-Supervisor | Versican: regulation, purification, and biological properties of a candidate prognostic indicator for breast cancer | Doctor of Philosophy | Doctorate | Full Time | Miss Supaporn Suwiwat |
Connect With Me
External Profiles
